Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

1

Trametinib was evaluated as a second-line treatment for advanced non-small cell lung cancer with KRAS G12C mutations in a retrospective study of 20 patients.
2

The objective response rate (ORR) for trametinib was 27.8%, while the disease control rate (DCR) was 72.2% among the patients studied.
3

The median progression-free survival (PFS) was 3.8 months, and the median overall survival (OS) was 8.6 months during the follow-up period.
4

Univariate analysis showed that patients without bone metastasis had a significantly higher ORR compared to those with bone metastasis.
5

Common treatment-related adverse reactions included rash (35%), diarrhea (25%), and fatigue (20%), with no grade 4 or higher adverse reactions reported.

1